arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

CHINA PHARMA HOLDINGS, INC.

CPHI
$1.12 ▼ -0.04 (-3.45%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
65 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

CHINA PHARMA HOLDINGS, INC. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $28.7M
Dividend Yield
Revenue Growth -13.4%
Op. Margin -113.6%
ROIC -2.4%
FCF / Share $-0.00
Trailing P/E
Price / Book 1.2x
FCF Yield
Debt / Equity 0.04
info Valuation on last close. End-of-day price, Aug 7, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$983.54K
↓ -13.4%
Net Income Profit after all expenses
$-1.14M
↓ -45.5%
Operating Margin Operating profit as % of sales
-113.6%
↓ -16.0% 3th
FCF / Share Free cash flow per share
$-0.00
↑ +93.9%
Long-Term Debt Long-term obligations
$4.33M
↓ -13.6%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
13
Returns
31
Financial Health
49
Cash Quality
21

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 65 quarters